MAPT and Alzheimer disease: Recent proteomic analyses of post‐translational modifications (PTMs) of tau revealed that pT217‐tau is a crucial, early phosphorylation epitope, distinguishing AD from other neurodegenerative disorders and indicative of disease progression.56